Amneal ownership update after Kashiv acquisition

Amneal Pharmaceuticals, Inc. completed the acquisition of Kashiv BioSciences, LLC, with its subsidiary Amneal Pharmaceuticals LLC purchasing 100% of Kashiv’s membership interests.

Rhea-AI Filing Summary

Amneal Pharmaceuticals, Inc. completed the acquisition of Kashiv BioSciences, LLC, with its subsidiary Amneal Pharmaceuticals LLC purchasing 100% of Kashiv’s membership interests. As consideration at closing, Amneal LLC was required to pay the sellers an aggregate of $375,000,000 in cash, and Amneal was required to issue an aggregate of 28,942,098 shares of Class A Common Stock to the sellers, including CKR Dynasty, LLC and Shivkan Holdings, LLC, entities associated with Chintu Patel.

Following these transactions, Chintu Patel is reported as the beneficial owner of 32,576,528 shares of Amneal Class A Common Stock, representing 9.4% of the class, based on 348,296,017 shares outstanding plus the 28,942,098 shares issued in the Kashiv acquisition. The reporting person holds shares directly, through options, and through various trusts and entities over which he has control, with sole voting and dispositive power over all reported shares.

Filing Explained

The amendment breaks Chintu Patel’s reported 32,576,528 beneficially owned shares into direct shares, two option positions, and holdings attributed to controlled trusts and entities; the options expire on May 7, 2028 and May 6, 2029.

Key Figures

Cash consideration for Kashiv Acquisition: $375,000,000 Shares issued in Kashiv Acquisition: 28,942,098 shares Beneficial ownership: 32,576,528 shares +5 more

8 metrics

Cash consideration for Kashiv Acquisition $375,000,000 Aggregate cash required to be paid to Kashiv sellers at closing

Shares issued in Kashiv Acquisition 28,942,098 shares Aggregate Class A shares required to be issued to Kashiv sellers

Beneficial ownership 32,576,528 shares Class A shares beneficially owned by Chintu Patel

Ownership percentage 9.4% Percent of Amneal Class A Common Stock beneficially owned by Chintu Patel

Shares outstanding baseline 348,296,017 shares Class A shares outstanding as of August 10, 2026, before Kashiv share issuance

CKR share issuance 2,807,963 shares Class A shares issued to CKR Dynasty, LLC in Kashiv Acquisition

Shivkan share issuance 3,573,771 shares Class A shares issued to Shivkan Holdings, LLC in Kashiv Acquisition

Stock option terms 24,977 @ $15.01; 28,044 @ $14.05 Options on Class A Common Stock held by Chintu Patel with 2028 and 2029 expirations

Key Terms

Schedule 13D, beneficially owned, Membership Interest Purchase Agreement, sole voting power, +2 more

6 terms

Schedule 13D regulatory

"This Amendment No. 5 to (this "Amendment No. 5") amends and supplements the filed with the SEC on July 9, 2018 (the "Initial 13D"..."

A Schedule 13D is a legal document that investors file with regulators when they buy a large enough stake in a company to potentially influence its management or decisions. It provides details about the investor’s intention, ownership stake, and plans, helping other investors understand who is gaining control and what their motives might be.

beneficially owned financial

"The following sets forth... the aggregate number of shares of Class A Common Stock and percentage of Class A Common Stock beneficially owned by the Reporting Person..."

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

Membership Interest Purchase Agreement regulatory

"entered into a Membership Interest Purchase Agreement (the "Purchase Agreement"), by and among the Issuer, Kashiv BioSciences, LLC..."

A membership interest purchase agreement is a contract used when someone buys an ownership stake in a limited liability company (LLC). It spells out what is being sold, the price, any promises about the business’s condition, and who takes responsibility for debts or legal issues—like a receipt and rulebook for the sale. Investors care because it transfers control, affects future cash flow and liabilities, and can change the value and tax treatment of their investment.

sole voting power financial

"Number of Shares Beneficially Owned by Each Reporting Person With: | 7 | Sole Voting Power 32,576,528.00"

Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.

sole dispositive power financial

"Number of Shares Beneficially Owned by Each Reporting Person With: | 9 | Sole Dispositive Power 32,576,528.00"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

Kashiv Acquisition financial

"purchased from the Sellers... 100% of the issued and outstanding membership interests of Kashiv (the "Kashiv Acquisition")."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stake in Amneal Pharmaceuticals (AMRX) does Chintu Patel report in this Schedule 13D/A?

Chintu Patel reports beneficial ownership of 32,576,528 shares of Amneal Class A Common Stock, representing 9.4% of the class, with sole voting and dispositive power over all of these shares as of August 10, 2026.

How did the Kashiv acquisition by Amneal Pharmaceuticals (AMRX) affect share issuance?

In the Kashiv acquisition, Amneal was required to issue an aggregate of 28,942,098 Class A shares to the sellers. This issuance is included in the ownership calculations and increased the total Class A shares used as the basis for the 9.4% stake.

What consideration was paid in Amneal Pharmaceuticals’ (AMRX) Kashiv acquisition?

For the Kashiv acquisition, Amneal’s subsidiary was required to pay an aggregate of $375,000,000 in cash to the sellers and Amneal was required to issue 28,942,098 Class A shares, with allocations including shares to CKR Dynasty, LLC and Shivkan Holdings, LLC.

How many Amneal (AMRX) shares related to the Kashiv acquisition went to CKR and Shivkan?

In connection with the Kashiv acquisition, CKR Dynasty, LLC was issued 2,807,963 Class A shares and Shivkan Holdings, LLC was issued 3,573,771 Class A shares, both entities being associated with Chintu Patel.

What options on Amneal Pharmaceuticals (AMRX) stock does Chintu Patel hold?

Chintu Patel holds options for 24,977 shares exercisable at $15.01 per share expiring May 7, 2028, and options for 28,044 shares exercisable at $14.05 per share expiring May 6, 2029, all for Class A Common Stock.

What share count underlies the 9.4% ownership figure for Amneal (AMRX)?

The 9.4% ownership figure is based on 348,296,017 Class A shares outstanding as of August 10, 2026, plus 28,942,098 Class A shares issued in the Kashiv acquisition, as reported in Amneal’s Form 10-Q and Form 8-K filings.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/12/2026 - 06:02 PM Accepted by SEC EDGAR 08/12/2026 - 06:01 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 5)

Amneal Pharmaceuticals, Inc.

(Name of Issuer)

Class A Common Stock, par value $0.01

(Title of Class of Securities)

03168L105

(CUSIP Number)

Christine Krentz
4 Gatehall Drive,
Parsippany, NJ, 07054
(908) 409-6700

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

08/10/2026

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

schemaVersion:

SCHEDULE 13D

CUSIP Number(s): 03168L105

1

Name of reporting person

Chintu Patel

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 32,576,528.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 32,576,528.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

32,576,528.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

9.4 %

14

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person:

The percentage of ownership of the Class A Common Stock by the Reporting Person presented in this Statement is based on 348,296,017 shares of Class A Common Stock outstanding as of August 10, 2026, which reflects the amount reported in the Issuer's Quarterly Report on Form 10-Q filed on August 6, 2026, plus 28,942,098 shares of Class A Common Stock issued in connection with the Kashiv Acquisition (as defined below), as reported in the Issuer's Current Report on Form 8-K filed on August 10, 2026.

SCHEDULE 13D

Item 1.	Security and Issuer
(a)	Title of Class of Securities: Class A Common Stock, par value $0.01
(b)	Name of Issuer: Amneal Pharmaceuticals, Inc.
(c)	Address of Issuer's Principal Executive Offices: 400 CROSSING BOULEVARD, 3RD FLOOR, BRIDGEWATER, NEW JERSEY , 08807.
Item 3.	Source and Amount of Funds or Other Consideration
	The disclosure in Item 3 is hereby amended and supplemented by adding the following: On April 21, 2026, CKR Dynasty, LLC, a Delaware limited liability company ("CKR") the sole manager of which is the Reporting Person, and Shivkan Holdings, LLC, a Delaware limited liability company ("Shivkan") the sole members of which are trusts controlled by the Reporting Person, entered into a Membership Interest Purchase Agreement (the "Purchase Agreement"), by and among the Issuer, Kashiv BioSciences, LLC ("Kashiv"), KB Seller Representative, LLC (the "Seller Representative") and the equityholders of Kashiv named therein, including CKR and Shivkan (the "Sellers"). On August 10, 2026, pursuant to the Purchase Agreement, Amneal Pharmaceuticals LLC, a Delaware limited liability company and wholly owned subsidiary of the Issuer ("Amneal LLC"), acting pursuant to the terms and conditions of a previously executed assignment and assumption agreement between it, Amneal, Kashiv and the Seller Representative, purchased from the Sellers, including CKR and Shivkan, and the Sellers, including CKR and Shivkan sold, conveyed, assigned, transferred and delivered to Amneal LLC, 100% of the issued and outstanding membership interests of Kashiv (the "Kashiv Acquisition"). Pursuant to the Purchase Agreement, at the closing of the Kashiv Acquisition, (i) Amneal LLC was required to pay to the Sellers, including CKR and Shivkan, an aggregate amount of $375,000,000 in cash, subject to certain purchase price adjustments, and (ii) Amneal was required to issue to the Sellers, including CKR and Shivkan, an aggregate of 28,942,098 shares of Class A Common Stock. CKR was issued 2,807,963 shares of Class A Common Stock, and Shivkan was issued 3,573,771 shares of Class A Common Stock, in connection with the Kashiv Acquisition.
Item 4.	Purpose of Transaction
	This Amendment No. 5 to Schedule 13D (this "Amendment No. 5") amends and supplements the Schedule 13D filed with the SEC on July 9, 2018 (the "Initial 13D" and, as amended and supplemented through the date of this Amendment No. 5, the "Schedule 13D"), by the Reporting Person relating to Class A Common Stock of the Issuer. Capitalized terms used but not defined in this Amendment No. 5 shall have the meanings set forth in the Schedule 13D.
Item 5.	Interest in Securities of the Issuer
(a)	The following sets forth, as of the date of this Schedule 13D, the aggregate number of shares of Class A Common Stock and percentage of Class A Common Stock beneficially owned by the Reporting Person, as well as the number of shares of Class A Common Stock as to which the Reporting Person has the sole power to vote or to direct the vote, shared power to vote or to direct the vote, sole power to dispose or to direct the disposition, or shared power to dispose or to direct the disposition of, as of the date hereof, based on 348,296,017 shares of Class A Common Stock outstanding as of August 10, 2026, which reflects the amount reported in the Issuer's Quarterly Report on Form 10-Q filed on August 6, 2026, plus 28,942,098 shares of Class A Common Stock issued in connection with the Kashiv Acquisition, as reported in the Issuer's Current Report on Form 8-K filed on August 10, 2026:
(b)	Reporting Person - Chintu Patel Amount beneficially owned - 32,576,528 Percent of class - 9.4 Sole power to vote or to direct the vote - 32,576,528 Shared power to vote or to direct the vote - 0 Sole power to dispose or to direct the disposition - 32,576,528 Shared power to dispose or to direct the disposition - 0 The Reporting Person owns directly (i) 1,388,521 shares of Class A Common Stock, (ii) 24,977 shares of Class A Common Stock issuable upon exercise of options exercisable for $15.01 per share, which expire on May 7, 2028 and (iii) 28,044 shares of Class A Common Stock issuable upon exercise of options exercisable for $14.05 per share, which expire on May 6, 2029; and may be deemed to beneficially own 11,495,965 shares of Class A Common Stock held of record by trusts controlled by the Reporting Person, 13,257,287 shares of Class A Common Stock held of record by Shivkan Holdings X, LLC, a Delaware limited liability company, 3,573,771 shares of Class A Common Stock held of record by Shivkan, and 2,807,963 shares of Class A Common Stock held by CKR.
(c)	The information set forth in Item 3 of this Amendment No. 5 is incorporated by reference herein
(d)	None.
(e)	Not applicable.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Chintu Patel

Signature:	/s/ Chintu Patel
Name/Title:	Chintu Patel
Date:	08/12/2026